Skip to main content
Midas Edge

Protagonist Therapeutics, Inc

For the period ended Jun 30, 2025. Filed Aug 6, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 6, 2025

PTGX$135.90+2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

​​​​​​​
​ · ​ · June 30, · ​ · December 31,
​20252024
Assets​​​​​​
Current assets:​​​​​​
Cash and cash equivalents​$168,543​$97,249
Marketable securities​​401,922​​321,664
Receivable from collaboration partner​​—​​165,000
Contract asset​​23,363​​—
Prepaid expenses and other current assets​​8,698​​7,728
Total current assets​​602,526​​591,641
Marketable securities - noncurrent​​102,493​​140,252
Property and equipment, net​​4,108​​3,190
Restricted cash - noncurrent​​290​​225
Operating lease right-of-use asset​​8,589​​9,417
Total assets​$718,006​$744,725
Liabilities and Stockholders’ Equity​​​​​​
Current liabilities:​​​​​
Accounts payable​$3,249​$1,615
Accrued expenses and other payables​​15,397​​23,693
Income taxes payable​​—​​2,689
Deferred revenue​​14,688​​18,891
Operating lease liability​​2,173​​510
Total current liabilities​​35,507​​47,398
Deferred revenue - noncurrent​​5,375​​11,676
Operating lease liability - noncurrent​​9,106​​10,356
Total liabilities​​49,988​​69,430
Commitments and contingencies​​​​​​
Stockholders’ equity:​​​​​​
Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding​​—​​—
Common stock, $0.00001 par value, 180,000,000 shares authorized; 62,107,572 and 61,035,139 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively​​1​​1
Additional paid-in capital​​1,054,980​​1,015,898
Accumulated other comprehensive loss​​(15)​​(82)
Accumulated deficit​​(386,948)​​(340,522)
Total stockholders’ equity​​668,018​​675,295
Total liabilities and stockholders’ equity​$718,006​$744,725
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.